BIOMAT Database Logo BIOMAT Database Logo

N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease. 2006

Gjin Ndrepepa, and Adnan Kastrati, and Siegmund Braun, and Julinda Mehilli, and Kathrin Niemöller, and Nicolas von Beckerath, and Olga von Beckerath, and Wolfgang Vogt, and Albert Schömig
Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany. ndrepepa@dhm.mhn.de

OBJECTIVE C-reactive protein (CRP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) provide prognostic information in patients with stable coronary heart disease. The aim of the study was to investigate whether combined use of NT-proBNP and CRP improves risk stratification in these patients. METHODS This cohort study included 989 patients with stable coronary heart disease who underwent coronary stenting. CRP and NT-proBNP were measured before angiography. The primary end point of the study was all-cause mortality. Using median values of NT-proBNP (279.9 ng/L) and CRP (1.2 mg/L), patients were divided into 4 groups: low NT-proBNP-low CRP group (305 patients with NT-proBNP<median and CRP<median); low NT-proBNP-high CRP group (190 patients with NT-proBNP<median and CRP> or =median; high NT-proBNP-low CRP group (237 patients with NT-proBNP> or =median and CRP<median); and high NT-proBNP-high CRP group (257 patients with NT-proBNP> or =median and CRP> or =median). RESULTS During a median follow-up of 3.6 years (interquartile range 3.3 to 4.5 years), there were 85 deaths: 6 deaths in the low NT-proBNP-low CRP group, 11 deaths in the low NT-proBNP-high CRP group, 20 deaths in the high NT-proBNP-low CRP group, and 48 deaths in the high NT-proBNP-high CRP group with Kaplan-Meier mortality estimates of 2.7%, 8.9%, 12.1% and 35.6%, respectively (P <.001). Cox proportional hazards model showed that combination NT-proBNP-CRP was the strongest independent correlate of mortality (hazard ratio [HR] 4.3, 95% confidence interval [CI], 2.0-9.3; P <.001 for high NT-proBNP-high CRP vs low NT-proBNP-low CRP). CONCLUSIONS Combined use of NT-proBNP and CRP improves long-term risk prediction of mortality in patients with stable coronary heart disease.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005858 Germany A country in central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark. The capital is Berlin.

Related Publications

Gjin Ndrepepa, and Adnan Kastrati, and Siegmund Braun, and Julinda Mehilli, and Kathrin Niemöller, and Nicolas von Beckerath, and Olga von Beckerath, and Wolfgang Vogt, and Albert Schömig
N-terminal probrain natriuretic peptide in patients with acute coronary syndrome
.
January 2017, International journal of clinical pharmacology and therapeutics,
Gjin Ndrepepa, and Adnan Kastrati, and Siegmund Braun, and Julinda Mehilli, and Kathrin Niemöller, and Nicolas von Beckerath, and Olga von Beckerath, and Wolfgang Vogt, and Albert Schömig
Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease.
May 2008, Coronary artery disease,
Gjin Ndrepepa, and Adnan Kastrati, and Siegmund Braun, and Julinda Mehilli, and Kathrin Niemöller, and Nicolas von Beckerath, and Olga von Beckerath, and Wolfgang Vogt, and Albert Schömig
Serum cardiac markers in patients with acute myocardial infarction: oxidative stress, C-reactive protein and N-terminal probrain natriuretic Peptide.
July 2007, Journal of clinical biochemistry and nutrition,
Gjin Ndrepepa, and Adnan Kastrati, and Siegmund Braun, and Julinda Mehilli, and Kathrin Niemöller, and Nicolas von Beckerath, and Olga von Beckerath, and Wolfgang Vogt, and Albert Schömig
N-terminal-probrain natriuretic peptide and echocardiography in patients with systolic heart failure.
November 2005, Saudi medical journal,
Gjin Ndrepepa, and Adnan Kastrati, and Siegmund Braun, and Julinda Mehilli, and Kathrin Niemöller, and Nicolas von Beckerath, and Olga von Beckerath, and Wolfgang Vogt, and Albert Schömig
Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma.
February 2001, Scandinavian journal of clinical and laboratory investigation,
Gjin Ndrepepa, and Adnan Kastrati, and Siegmund Braun, and Julinda Mehilli, and Kathrin Niemöller, and Nicolas von Beckerath, and Olga von Beckerath, and Wolfgang Vogt, and Albert Schömig
N-terminal probrain natriuretic peptide as biomarker for diagnosis of Kawasaki disease.
March 2019, Biomarkers in medicine,
Gjin Ndrepepa, and Adnan Kastrati, and Siegmund Braun, and Julinda Mehilli, and Kathrin Niemöller, and Nicolas von Beckerath, and Olga von Beckerath, and Wolfgang Vogt, and Albert Schömig
N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.
February 2005, The New England journal of medicine,
Gjin Ndrepepa, and Adnan Kastrati, and Siegmund Braun, and Julinda Mehilli, and Kathrin Niemöller, and Nicolas von Beckerath, and Olga von Beckerath, and Wolfgang Vogt, and Albert Schömig
Variability of N-terminal probrain natriuretic peptide in stable chronic heart failure and its relation to changes in clinical variables.
May 2009, Clinical chemistry,
Gjin Ndrepepa, and Adnan Kastrati, and Siegmund Braun, and Julinda Mehilli, and Kathrin Niemöller, and Nicolas von Beckerath, and Olga von Beckerath, and Wolfgang Vogt, and Albert Schömig
Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease.
January 2006, Archives of internal medicine,
Gjin Ndrepepa, and Adnan Kastrati, and Siegmund Braun, and Julinda Mehilli, and Kathrin Niemöller, and Nicolas von Beckerath, and Olga von Beckerath, and Wolfgang Vogt, and Albert Schömig
Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy.
September 2007, Heart and vessels,
Copied contents to your clipboard!